Physician profile
John B Pope
NPI 1588682058
$5,576.31
in general payments reported to CMS, 2019-2025
33 companies · $835 in 2025
The $835 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $525 · 2021: $1,264 · 2022: $1,030 · 2023: $844 · 2024: $603 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,281.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $771.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $753.99 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.98 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $405.89 | 2019-2025 | Belsomra, Steglatro, Gardasil 9 |
| Lilly USA, LLC | $376.45 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $349.88 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $322.13 | 2020-2025 | Evenity, Prolia |
| Pfizer INC. | $243.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.94 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $217.13 | 2019-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.76 | 2020-2022 | |
| Astellas Pharma US INC | $138.75 | 2019-2025 | Veozah |
| Allergan, INC. | $121.80 | 2020 | |
| Abbott Laboratories | $120.88 | 2022-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $118.98 | 2024-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $84.75 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $76.78 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $76.01 | 2021-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $67.15 | 2019 | |
| Exact Sciences Corporation | $60.13 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $56.13 | 2022 | |
| Shire North American Group INC | $50.96 | 2019 | |
| Shield Therapeutics INC | $36.20 | 2025 | |
| Eisai INC. | $34.12 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $30.81 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $28.13 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $28.02 | 2021 | |
| Ethicon US, LLC | $20.92 | 2019 | |
| Abiomed | $18.14 | 2025 | |
| Corcept Therapeutics | $17.93 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $16.58 | 2021 | |
| Amarin Pharma, INC. | $14.53 | 2020 | |
| Esperion Therapeutics, INC. | $13.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.